Biogen
-
-
-
US FDA gives nod to first and only oral treatment for Postpartum Depression
USA – The United States Food and Drug Administration (FDA), has approved Biogen’s and Sage Therapeutic’s oral medication for the treatment of postpartum depression (PPD)…
-
Biogen finalizes deal to acquire Reata Pharmaceuticals for US$7.3B
USA—Biogen Inc. and Reata Pharmaceuticals, Inc., have announced that they have reached a definitive agreement where Biogen has agreed to acquire Reata for $172.50 per share…
-
Biogen announces job cuts and shifts focus to new Alzheimer’s drug amidst challenging times
USA —In a bid to navigate turbulent waters and reignite growth, Biogen Inc, a U.S. drugmaker, is set to slash around 1,000 jobs, constituting 11%…
-
FDA grants full approval to Leqembi, a groundbreaking drug slowing disease progression
USA —The U.S. Food and Drug Administration (FDA) has granted traditional full approval to Leqembi, a breakthrough medication for Alzheimer’s disease. This marks a significant…
-
Biogen shareholders embrace change with election of new board member
USA —Biogen, a leading biotechnology company, has undergone a significant shift in its board of directors as shareholders elected a new member during a recent…
-
Biogen’s boardroom harmony takes shape as three directors step down
USA — Biogen, a renowned biotechnology company, has announced significant changes to its board of directors, with three members deciding not to seek re-election. This…
-
Biogen contemplates legal action following Merck’s lawsuit against US Medicare drug pricing
USA —Biogen CEO Chris Viehbacher has expressed his intention to explore the possibility of taking legal action similar to Merck & Co.’s recent lawsuit against…
-
Biogen continues restructuring, cuts Multiple Sclerosis team
USA — Biogen has laid off an undisclosed number of employees, including members of its multiple sclerosis (MS) team, as part of a plan to…